COMBINE_logo.png

 

 

COMBINE_-_Mike_Kappelman_V2.png

Purpose: The COMBINE trial will study if treatment with a single anti-TNF medication (infliximab and adalimumab) or dual therapy that includes methotrexate is more effective in children with moderate to severe Crohn’s disease. COMBINE is the first study to look at this question in children with Crohn’s disease. We expect that 425 kids from across the US will enter the study. The results of this study can be used to help doctors choose medications that help children the most.

Funding Source (Year Awarded): Patient Centered Outcomes Research Institute (2015)

Study Period: 2015-2020

Recruitment Status: Currently recruiting participants 

Contact: Michelle Robinson, Project Manager, UNC 

For more information

COMBINE Trial Website

Care Centers - Find a participating COMBINE center

LOOP blog posts

The COMBINE Study

Built by Veracity Media on NationBuilder